Cohbar Inc Stock Price, News & Analysis

CohBar, Inc. (NASDAQ: CWBR) announced its CEO, Joseph Sarret, will participate in the BIO webinar on December 2, 2021, at 1:00pm ET. This session, featuring notable executives from various biotech firms, aims to help attendees strategize for JPM Week. CohBar focuses on developing mitochondria-based therapeutics to treat chronic diseases. The company’s lead compound, CB4211, recently completed a Phase 1a/1b trial for NASH and obesity, while CB5138-3 targets idiopathic pulmonary fibrosis. Registration for the webinar is free and available online.

CohBar, Inc. (NASDAQ: CWBR) reported its third-quarter financial results for 2021, highlighting significant progress in its clinical studies and financial standing. The company showcased positive topline data from its Phase 1a/1b study of CB4211 for NASH and obesity, meeting primary endpoints while demonstrating safety and tolerability. CohBar also secured a U.S. patent for CB4211, completed a $15M financing, and recently gained coverage from Cantor Fitzgerald. However, cash reserves decreased from $21M to $15M, and net loss rose to $3.4M, or $0.05 per share.

CohBar, Inc. (NASDAQ: CWBR) plans to release its third quarter 2021 financial results after market closure on November 15, 2021. The company, engaged in developing mitochondria-based therapeutics for chronic diseases, will host a conference call at 5:00 p.m. ET to discuss these results and provide a business update. Interested participants can dial in using the provided numbers. An audio replay will be available from 8:00 p.m. ET on November 15 through December 6, 2021.

CohBar, Inc. (NASDAQ: CWBR) announced an underwritten public offering of 20,833,334 shares of common stock and warrants at $0.72 each, aimed at raising approximately $15.0 million before expenses. The offering is set to close around November 1, 2021, subject to standard conditions. Funds will support general corporate purposes, including preclinical and clinical developments. Cantor Fitzgerald & Co. is the lead manager, with Brookline Capital Markets assisting. The offering leverages an existing SEC registration effective since August 24, 2020.

CohBar, Inc. (NASDAQ: CWBR) announced a proposed underwritten public offering of its common stock and accompanying warrants. The offering, managed by Cantor Fitzgerald & Co. and Brookline Capital Markets, is subject to market conditions and uncertainties regarding completion. Proceeds will be utilized for general corporate purposes, including funding clinical developments and operating expenses. The offering will be conducted pursuant to an effective shelf registration statement filed with the SEC. There is no assurance on the offering's size or terms.

CohBar, Inc. (NASDAQ: CWBR) announced that data from its Phase 1a/1b study of CB4211, aimed at treating nonalcoholic fatty liver disease (NAFLD), will be presented at the AASLD Annual Meeting from November 12-15, 2021. The trial showed significant reductions in ALT, AST, and glucose levels after four weeks of treatment. CB4211 is a novel mitochondria-based therapeutic also targeting nonalcoholic steatohepatitis (NASH) and obesity. The presentation will be given by Dr. Rohit Loomba, with the findings set to influence future clinical research and treatment strategies.

CohBar (NASDAQ: CWBR) announced that its CEO, Dr. Joseph Sarret, will present an overview of the company at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021, at 12:00pm ET. The presentation will cover the company’s focus on mitochondria-based therapeutics for chronic diseases. CohBar has made significant advancements, including a successful Phase 1a/1b trial for CB4211, targeting NASH and obesity. A replay of the webcast will be available for two weeks following the event.

CohBar, Inc. (NASDAQ: CWBR) appointed Dr. Joanne Yun as an independent director effective September 14, 2021. Dr. Yun brings extensive experience from the pharmaceutical sector, having held key positions in research, development, and strategic planning. Her expertise is expected to enhance CohBar's mission to develop mitochondria-based therapeutics for chronic diseases. This includes the promising CB4211 compound, which has shown positive results in clinical trials. The Board's confidence in Dr. Yun's capabilities suggests potential future success in advancing the company's therapeutic pipeline.

CohBar, Inc. (NASDAQ: CWBR) has announced the grant of U.S. Patent No. 11,111,271, protecting its lead candidate CB4211 for treating nonalcoholic steatohepatitis (NASH) and obesity. This patent extends to at least 2037, strengthening CohBar's intellectual property portfolio which now includes 13 patents. CB4211 has completed a successful Phase 1a/1b clinical trial, demonstrating positive effects on liver injury and metabolic health. The company aims to secure comprehensive patent protection while advancing its innovative mitochondria-based therapeutics.